Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Neutrophil-to-lymphocyte ratio predicts mortality in seniors with head and neck cancer

04 Apr 2020
Much more research is required to fully establish the connection.

The neutrophil-to-lymphocyte ratio (NLR) may hold prognostic value for mortality in elderly adults with head and neck squamous cell carcinoma (HNSCC), a recent study has shown.

Researchers conducted a prospective evaluation of 233 consecutive elderly HNSCC patients (median age, 71 years; 84.5 percent male). Blood samples were drawn and used for the calculation of NLR. Participants also underwent performance status and comorbidity assessments using the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) and Charlson Comorbidity Index (CCI) tools.

The pretreatment median NLR value was 1.9. More than half of the participants (55.4 percent) had overall stage III or IV cancer, while 35.2 percent (n=82) had advanced T3 or T4 malignancies. Over a median follow-up of 53 months, 26.6 percent of the survivors developed tumour recurrence, mostly in local sites. At last follow-up, 63.1 percent (n=147) were alive without disease and 57 had died of HNSCC.

Multivariate Cox proportional hazards regression models found that an NLR value >2.5 was a significant risk factor for overall mortality (hazard ratio [HR], 1.77, 95 percent confidence interval [CI], 1.05–2.97; p=0.031).

The same was true when stratifying according to cause: NLR upped the likelihood of dying from cancer (OR, 1.89, 95 percent CI, 1.09–3.29; p=0.023) or from noncancer causes (OR, 6.29, 95 percent CI, 2.16–18.37; p=0.001).

Other significant predictors included age >75 years, comorbidities and frailty.

“Of laboratory tests, NLR may be used as a circulating prognostic marker for mortality in old-aged patients with HNSCC. Future studies might be performed to examine the usefulness of prognostic markers including NLR in terms of treatment outcomes, toxicity, and complications in the older patients,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.